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INTRODUCTION
Peripheral neuritis is a well-known complication
of isoniazid therapy.  It rarely occurs when small
dosages of the drug are used (great Britain, Medical
Research Council, 1952, 1953a, 1953b, 1955;
Mount, Henkins & Ferebee, 1953; Tuberculosis
Chemotherapy Centre, 1959), although Money
(1959) encountered a high incidence of the
neuropathy in malnourished tuberculous patients in
East Africa on a comparatively low dosage of
isoniazid (4 mg/kg to 6 mg/kg body-weight daily).
The complication is more frequent with higher
dosages of isoniazid (gammon, Burge & King, 1953;
United States Public Health Service, 1954; Biehl &
Nimitz, 1954; Wood, 1955; Tchertkoff et al., 1956).
This paper reports 20 cases of peripheral neuritis
encountered in a controlled chemotherapeutic trial
of four regimens in patients with active pulmonary
tuberculosis undertaken at the Tuberculosis
Chemotherapy Centre, Madras.  The patients
allocated to two of the regimens received a low
dosage of isoniazid (in practically all patients 3.9
mg/kg to 5.5 mg/kg body-w3eight daily) and those
allocated to the remaining two regimens received a
moderately high dosage of the drug (7.8 mg/kg to
9.6 mg/kg bodyweight daily). The patients were
drawn from the lower income groups in Madras City
and were on a poor diet (Tuberculosis Chemotherapy
Centre, 19601). Alcohol has been prohibited in
Madras State for the past 12 years and none of the
patients, as far as is known, was an alcoholic.
PLAN AND CONDUCT OF THE CHEMOTHERAPY STUDY
In all, 341 patients with active pulmonary
tuberculosis were allocated at random to four
regimens of antituberculosdis chemotherapy for a
year.  Three of these patients have been excluded
from this report because they had previously
received chemotherapy which included isoniazid.
The four regimens were
PH (96 patients)
These patients received cachets each containing
isoniazid 25 mg and PAS 1.25 g. The number of
cachets prescribed depended on the patient’s weight
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It is well known that in the treatment of tuberculosis with isoniazid the complication of
peripheral neuritis may arise.   This complication is normally rare when small dosages of the
drug are used, but a hig incidence of the neuropathy has recently been observed in East Africa
in a group of malnourished truberculous patients receiving isoniazid in comparatively low dos-
age (4-6 mg/kg body-weight daily).  The present paper reports on 20 cases of peripheral neuritis
encountered in Madras, India, among 338 poorly nourished tuberculous patients during a trial
of four isoniazid regimens, two of low and two of high dosage (3.9-5.5 and 7.8-9.6 mg/kg body-
weight daily respectively).  Nineteen of the 20 cases occurred in the two groups of patients
receiving the high dosage and these 19 patients were found to have a higher mean serum level of
free isoniazid than the patients in the same groups who did not develop the complication. The
authors consider that dosages of 7.8-9.6 mg/kg body-weight daily should not be used for the
mass therapy of poorly nourished patients unless steps are taken to prevent the development of
peripheral neuritis.  Pyridoxine has been reported to be an effective preventive, but is too expen-
sive for use on a large scale.  This study indicates, however, that administration of the cheaper
vitamin B complex might give satisfactory results and warrants further investigation.
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the World Health Organization, and the Medical Research
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TABLE 1
DAILY DOSAGE OF ISONIAZID IN RELATION TO BODY-WEIGHT
Treatment
series
PH and H
HI-l
HI-2
Body-weight
(lb.) (kg) morning evening
45-59 20.4-27.1 3
60-79 27.2-38.2 3
80-99 36.3-45.3 3
100-119 45.4-54.3 4
45-59 20.4-27.1 4
60-69 27.2-31.7 5
70-79 31.8-36.2 6
80-99 38.3-45.3 7
100-109 45.4-49.8 8
110-119 49.9-54.3 9
45-59 20.4-27.1 2
 60-69                                        27.2-31.7 2
70-79 31.8-36.2 3
80-99 36.3-45.3 3
100-109 45.4-49.8 4
110-119 49.9-54.3 4
3
3
4
4
0
0
0
0
0
0
2
3
3
4
4
5
No. of tablets or cachets
prescribed daily
(Table 1). The dosage of isoniazid ranged from
3.9 mg/kg to 5.5 mg/kg body-weight, approximately,
and the dosage of PAS from 0.2 g/kg to 0.3 g/kg
body-weight, daily. The cachets were to be taken
in two doses each day.
H (94 patients)
These patients received tablets each containing
25 mg of isoniazid. The dosage range of isoniazid
was the same as that for the PH patients and the
tablets were to be taken in two doses each day
(Table 1).
HI-1 (74 patients); HI-2 (74 patients)
The patients in both the HI-1 and the HI-2 series
received tablets containing 50 mg of isoniazid, the
total daily dosage ranging from 7.8 mg/kg to
9.6 mg/kg body-weight, approximately (Table 1).
The HI-I patients were to take the drug in one dose
in the morning, and the HI-2 patients in two doses,
one in the morning and the other in the evening.
The great majority of the patients were ambulant
and attended the Centre weekly to collect their supply
Total daily Daily dosage of
dosage of isoniazid in relation
isoniazid
(mg)
to body-weight
(mg/kg)
150 7.3-5.6
150 5.5-4.2
175 4.8-3.9
200 4.4-3.7
200 9.8-7.5
250 9.2-8.0
300 9.4-8.4
350 9.6-7.8
400 8.8-8.1
450 9.0-8.3
200 9.8-7.5
250 9.2-8.0
300 9.4-8.4
350 9.6-7.8
400 8.8-8.1
450 9.0-8.3
of medicine. They were examined monthly as a
routine. If, at a monthly examination, a patient
was found to have gained weight and to have moved
into a higher weight category, the number of cachets
or tablets was increased appropriately; if a patient
had lost weight and had fallen into a lower weight
category, the number was not decreased. All patients
continued on the allocated regimen for 12 months,
unless a radiographic deterioration or a severe toxic
reaction to either of the drugs, necessitating a change
of chemotherapy, had occurred. At the end of
12 months, patients with bacteriologically quiescent
disease were allocated at random, either to isoniazid
alone prescribed as a single tablet daily, the dosage
being the same as in the H regimen, or to no further
specific chemotherapy. Patients who still had
active disease at the end of 12 months continued on
the originally prescribed chemotherapy.
DIAGNOSIS OF PERIPHERAL NEURITIS
A record was kept of any spontaneous complaint
which could be attributed to peripheral neuritis.
The patients were not questioned to elicit symptoms,
PERIPHERAL NEURITIS DUE TO ISONIAZID 589
TABLE 2
INCIDENCE AND TIME OF ONSET OF PERIPHERAL NEURITIS IN THE
TWO HIGH-DOSAGE ISONIAZID SERIES
treatment
1
2
3
4
5
6
7
8
9
10
1 1
12
HI-1 HI-2
cases of peripheral neuritis cases of
new cases
0
2
2
3
2
0
1
1
1
1
0
0
cumulative total
No. %
0 0
2 3
4 5
7 10
9 12
9 12
10 14
1 1 15
12 16
13 18
13 18
13 18
nor was the Centre’s nursing staff informed of the
possible occurrence of the neuropathy. A physical
examination was not performed when a patient first
made a spontaneous complaint, unless the symptoms
were prominent. If the symptoms persisted, neuro-
logical examinations were performed, the frequency
depending on the severity of the symptoms. If any
physical sign of peripheral neuritis was obtained,
the patient was referred to an independent assessor,
who was unaware of the patient’s chemotherapeutic
regimen. Of the 20 cases who form the subject
of this report, the diagnosis was confirmed by an
independent assessor in 18. The other two patients
developed peripheral neuritis early in the study
before the procedure of examination by an indepen-
dent assessor had been established. With increasing
experience of the symptoms and signs presented by
isoniazid peripheral neuritis, there was a tendency
for cases to be referred earlier for an independent
assessment. Dr K. S. Sanjivi and Dr C. E. Klontz
acted as the independent assessors.
INCIDENCE AND ONSET
One (1%) of 96 PH, none of 94 H, 13 (18%) of 74
HI-1 and six (8%) of 74 HI-2 patients developed
new cases
0
0
2
0
0
0
2
1
0
1
0
0
peripheral neuritis
cumulative total
No. %
0 0
0 0
2 3
2 3
2 3
2 3
4 5
5 7
5 7
 6 8
6 8
6 8
peripheral neuritis in 12 months. (An account of
the PH patient is given separately on page 592.) The
cumulative incidence month by month for the HI-l
and HI-2 series is shown in Table 2 and in the figure
overleaf. The month in which a patient first made a
spontaneous complaint has been regarded as the
month of onset even if the physical signs did not
develop until later. The difference in the cumulative
incidence of peripheral neuritis between the two
series did not attain statistical significance in any
month of treatment. The time of onset lay between
the second and the tenth month. Nine of 13 patients
in the HI-1 series compared with two of six in the
HI-2 series first presented symptoms in the first six
months of treatment.
Seven HI-1 and 14 HI-2 patients failed to complete
12 months on the allocated regimens either because
they had shown radiographic deterioration and their
treatment had been changed, or because they had
discharged themselves against medical advice, or
because they had died. The incidence of the neuro-
pathy in 12 months among the remaining patients
was 13 (19 %) of 67 HI-1 patients and six (10 %) of
60 HI-2 patients. It will be appreciated that the
figures based on all the patients allocated to a regimen
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CUMULATIVE PERCENTAGES OF PATIENTS IN THE HI-1 AND HI-2 SERIES WHO DEVELOPED PERIPHERAL NEURITIS
DURING THE 12 MONTHS
represent an underestimate and the figures based on
only those who completed 12 months of isoniazid
therapy an overestimate of the true incidence of
peripheral neuritis.
CLINICAL FEATURES
The clinical features of the peripheral neuritis
in the HI-1 and HI-2 series were similar. The first
symptoms were always paraesthesiae, confined to
the feet in some patients but also involving the
hands in others. The symptoms consisted of one
or more of the following: burning sensation,
pricking pain, feeling of numbness or tingling.
Three patients also complained of weakness of the
hands; two were unable to button their shirts and
the third, an artist, had difficulty in holding his
brush.
Physical signs
Some of the more important physical signs
elicited in the 19 patients were:
Motor signs. Muscular weakness of the limbs
(five patients). This involved the feet in all five
patients and the hands in three of them.
Reflexes :
(a) Loss of ankle jerks (14 patients).
(b) Loss of knee jerks (three patients).
Sensory signs :
(a) Loss of light touch (eight patients). This was
confined to the feet in three patients; it also involved
the lower third of the legs in one patient, the lower
half in three patients and the lower two-thirds in
one patient. The last-mentioned patient also had
anaesthesia over the right side of the face and over
the right shoulder and scapular region.
(b) Loss of pain sensation (four patients). The
area of analgesia involved both feet in two of the
patients, extended to the middle of the legs in one
and rather higher in the fourth.
(c) Loss of position sense in the toes (seven
patients).
(d) Loss of vibration sense (16 patients).  The
loss of this modality occurred in the toes in all 16
patients and extended to the ankles in nine of them.
(e) Tenderness of the calf muscles (five patients).
Course
The usual course was a slow progression of the
symptoms and a gradual spread of physical signs
proximally.  Two cases, however, presented an acute
onset and a rapid progression.  Usually, the first signs
elicited  were loss of vibration sense in the toes and
loss of ankle jerks, followed by anaesthesia and loss
of position sense.  The more severe cases developed
loss of knee jerks and muscular weakness, but none
showed any severe motor disability such as foot
drop.
Other features
One patient (HI-1), in whom the symptoms were
rapidly progressive, complained of a severe burning
sensation in the feet, which exhibited excessive
sweating and extreme flushing. These
manifestations were worse at night and prevented
sleep. The symptomatology in this case was very
similar to that encountered by Money (1959) in three
of 16 patients with isoniazid peripheral neuritis, and
which he terms, “vasculo-neuropathy”. Another
patient (HI-1) exhibited signs of mental disturbance
coincident with the onset of symptoms of peripheral
neuritis. He was extremely apprehensive and had
premonitions of death. One patient (HI-1) also had
other signs of vitamin B deficiency-namely, glossitis
and angular stomatitis.
TREATMENT AND RESPONSE
Treatment
1.Nine cases, encountered early in the study,
were treated with pyridoxine. In eight of these the
isoniazid was stopped and pyridoxine was given
orally in a dose of 200 mg daily. It was also given
intramuscularly for the first three months, as 300
mg in one injection daily for the first two weeks,
then 300 mg twice a week for six weeks, and in the
third month 300 mg once a week. The remaining
case continued to receive the high dosage of
isoniazid and was given pyridoxine orally, in a dose
of 120 mg daily, for two months only.
2.Seven cases, encountered later in the study,
were treated with a vitamin B complex preparation,
two tablets, three times a day. (the stated formula
per tablet was: thiamine, 10 mg; riboflavine, 5mg;
pyridoxine; 1mg; niacinamide, 50 mg; panthenol,
3mg; cyanocobalamine, 1ag. In order to ensure that
each tablet contained these minimum quantities
unti8l their date of expiry, extra active principle was
added as a routine  by the manufactures-namely 33%
more of thiamine, 10% of panthenol and 50% of
cyano cobalamine.) Four1 of the seven patients
continued on the high dosage of isoniazid and in
one isoniazid was stopped. The remaining two
patients were on a low dosage of isoniazid when
treatment with vitamin B complex was commenced
in the second year (see page 588), although their
initial symptoms of peripheral neuritis occurred in
the first year of chemotherapy.
3. Three patients with very mild peripheral
neuritis did not receive any specific treatment for it.
Response
The response of the patients to the above
regimens has been as follows:
1.The eight patients treated with pyridoxine, with
the discontinuation of isonaizid, have received it for
almost a year at the time of writing. They have
shown very slow but definite amelioration of the
symptoms and signs. All three patients in this group
who had developed muscular weakness in the limbs
have gradually regained power. The paraesthesiae
have disappeared completely in one and improved
in seven. The ankle jerks are still absent in all of
them, but one of three patients has regained the knee
jerks. Of the five patients with anesthesia, three have
regained sensation and in two the area affected has
diminished. All the three patients who had lost
sensation to pain in the lower limbs have regained
this modality and three of four patients have regained
position sense. All eight patients had lost vibration
sense at the ankles and toes; six have regained this
modality at the ankles but none so far has regained
it in the toes. The patient who was mentally disturbed
became normal within three months. Although these
eight patients are left with some neurological signs,
all except one are leading a normal life and are in
fulltime employment-four as housewives, one as a
mill worker, one as a salesman and one as a car
driver. The exception is a patient who is in
sanatorium because his pulmonary tuberculosis
needs further treatment. The patient who continued
1
 Two of these four patients received yeast tablets initially
for some weeks instead of vitamin B complex.
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on the high dosage of isoniazid and received
pyridoxine lost his symptoms.
2. Of the patients who were treated with vitamin
B complex, the four who continued on hte high
dosage of isoniazid have received the vitamin
preparation for a period of nine months, seven
months, four months and three months, respectively,
at the time of writing. They had developed only
limited physical signs when treatment for the
neuropathy was commenced. There was no
progression of the symptoms and signs even though
they continued to receive the high dosage of
isoniazid. Tow of them are now completely
asymptomatic and the other two have improved. The
patient who received vitamin B complex with the
discontinuation of isoniazid therapy became
completely asymptomatic in two months.
The two patients who first received vitamin B
complex in the second year were then on isoniazid
in a reduced dosage –namely, 4.2 mg/kg and 4.4 mg/
kg daily, respectively. They have received vitamin
B complex for seven months and five months,
respectively, at the time of writing. Both have
improved and are leading a normal life, one of them
being completely asymptomatic.
3.The symptoms in the three patients with very
mild neuritis, who continued on high isoniazid
dosage but received no treatment for this
complication, disappeared spontaneously, although
the minimal physical signs still remain.
NOTES ON A TYPICAL CASE OF PERIPHERAL
NEURITIS
A male aged 47 years commenced HI-1 regimen
on 16.11.58. He had received on the average 8.4
mg/kg body-weight of the drug daily when he first
complained of a feeling of numbness in the hands
and feet on 19.3.59. These symptoms persisted and
a neurological examination on 26.3..59 revealed loss
of both ankle jerks and of vibration sense in the toes.
There was a gradual spread of the paraesthesiae
proximally (without the development of fresh
physical signs) and treatment with yeast wasd begun
on 23.4.59 while he continued to receive isoniazid.
From 7.5.59 onwards he received vitamin B complex
(two tablets three times a day) instead of yeast. After
seven months of treatment the symptoms have
improved but the signs still persist. He has returned
to full-time employment as a workshop instructor.
This patient received isoniazid for the full 12
months, even though the peripheral neuritis
presented in the fifth month of treatment.
THE PH PATIENT WHO DEVELOPED PERPHERAL
NEURITIS
One of the 96 patients in the PH series developed
peripheral neuritis. This was a woman aged 45 years
who had received isoniazid in an average dose of
4.9 mg/kg bogy-weight daily when she first
complained of paraesthesiae in the seventh month
of treatment. By the thirteenth month she had
developed muscula weakness of the limbs,
tenderness of the calf muscles, loss of ankle jerks
and loss of vibration and position sense in the toes,
even though treatment had been stopped at one year
as the disease was quiescent. At the time of writing
she has received vitamin B complex for two months
and her symptoms have improved. She is leading a
normal life as a housewife.
AGE SEX AND ECONOMIC STATUS
Combining the HI-1 and HI-2 series there was a
greater incidence of peripheral neuritis in the older
age-groups –namely, eight (17%) of the 47 patients
aged 35 years or more compared with 11 (11%) of
101 patients under 35 years of age; the difference
does not attain statistical significance. Of the 96
males, 12 (13%) developed peripheral neuritis
compared with seven (13%) of 52 females.
The patients in this study came from a poor
section of the community in Madras city
(Tuberculosis Chemotherapy Centre, 19601) but
there as no association between the family incomes
of the patients and the development of peripheral
neuritis.
TOTAL DAILY DOSAGE
The average daily dosage of isoniazid prescribed
for each patient up to the time of the first
spontaneous complaint attributable to peripheral
neuritis was calculated. This was found to be 8.6
mg/kg body-weight daily for the 13 HI-1 patients
and 8.7 mg/kg body-weight daily for the six HI-2
patients.  Similar calculations were made for the
whole 12 months or until isoniazid therapy was
changed, if this was earlier than 12 months, for the
61 HI-1 patients and the 68 HI-2 patients who did
not develop peripheral neuritis. The mean value for
the control HI-1 group was 8.7 mg/kg and for the
1
 See article on page 535 of this issue.
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HI-2 group was 8.6 mg/kg body-weight daily. In
both series the isoniazid dosage for the patients who
developed peripheral neuritis and for those who did
not was, therefore, closely similar.
SERUM ISONIAZID ASSAYS
Serum isoniazid estimations were performed on
143 of the 148 patients on the HI-1 and HI-2
regimens. All chemotherapy was stopped for 48
hours before the day of the test. Each patient
received an intramuscular dos of isoniazid of  mg/
kg bodyweight and the concentration of free
isoniazid in the serum four-and-a-half hours later
was estimated by microbiological assay. The full
details of this method will be reported elsewhere
(Gangadharam et al., to be published).
Table  3 gives the distributions of the serum
isoniazid levels of the patients who developed
peripheral neuritis and of those who did not in the
HI-1 and HI-2 series.  The mean serum isoniazid
level was 0.53 ag/ml for the HI-1 patients who did
not develop peripheral neuritis as compared with
0.99 ag/ml, respectively. (The serum isoniazid level
of the patient who developed peripheral neuritis in
the PH series was 0.82 ag/ml)
The patients with serum isoniazid levels of 0.60
ag/ml or higher have been regarded as slow
inactivators of isoniazid and those with levels below
0.60 ag/ml as rapid inactivators (Gangadharam et
al., to be published) Eleven (28%) of 39 slow
inactivators compared with two (6%) of 32 rapid
inactivators developed peripheral neuritis in the HI-
1 series. This difference attains statistical
significance (P>0.10). Combining the HI-1 AND
HI-2 series, the difference between the incidence of
peripheral neuritis in the slow and in the rapid
inactivators of isoniazid attains statistical
significance (P<0.01).
There was no association between the serum
isoniazid level and the month of treatment in which
peripheral neuritis developed.
Although the test dose of isoniazid was
proportional to the body-weight, the lighter patients
were found to have lower serum levels than the
heavier ones in this investigastion (Gangadharam
et al., to be published) in agreement with the findings
of Evans (1959). However, an analysis (not tabulated
here) did not reveal any association between the
weights before or during treatment and the
development of peripheral neuritis.
REGULARITY IN SELF-ADMINISTRATION OF ISONIAZID
In this study one of the methods used to
determine whether patients were taking the isoniazid
tablets regularly was to test the urine for the presence
of the drug (Gangadharam et al., 1958; Tuberculosis
Chemotherapy Centre, 19601 ) at the routine weekly
visits of the patients to the Centre. Since the results
of this test might differ among slow and rapid
inactivators and since 17 of the 19 patients who
developed peripheral neuritis were slow activators
of isoniazid, an analysis was undertaken to see
whether there was any association between the
regularity of the self-administration of isoniazid and
the development of the neuropathy among the slow
inactivators. Table 4 related the percentage of urine
tests with negative results to the frequency of the
development of peripheral neuritis among the slow
inactivators in the HI-1 and HI-2 series. Combining
the two series, 13(34%) of 38 patients, all of whose
1
 See article on page 535 of this issue.
patients
without
peripheral
neuritis
TABLE 3
DISTRIBUTION OF SERUM ISONIAZID LEVELS
Serum
Isoniazid
levels
(mg/ml)
HI-1 HI-2
patients
with
peripheral
neuritis
patients
without
peripheral
neuritis
patients
without
peripheral
neuritis
Rapid inactivation of isoniazid
<0.18 4 0 1 0
0.18- 5 0 5 0
0.25- 12 0 13 0
0.35- 6 1 4 0
0.49- 3 1 5 0
Slow inactivation of isoniazid
0.60- 2 1 2 1
0.70- 4 2 6 0
0.99- 14 6 23 5
1.39- 3 2 5 0
1.97- 5 0 2 0
>2.78 0 0 0 0
Total
patients 58 13 66 6
Mean
(µg/ml) 0.53 0.99 0.62 0.96
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urine tests were positive, developed the neuropathy
compared with four (9%) of 45 patients whose urine
specimens were negative on one or more occasions.
This difference is statistically significant (P=0.01).
Considering the two series separately, the
corresponding difference attains statistical
significance in the HI-1 series (P=0.01) bur does
not do so in the HI-2 series.
The 11 slow inactivators in the HI-1 series who
developed peripheral neuritis had a total of 235 urine
tests at their routine visits to the Centre during the
year (the tests performed after the onset of symptoms
not being considered) of which three (1.3%) were
negative. In contrast, the 28 slow inactivators in the
HI-1 series who did not develop this complication
had 1361 such tests during the year of which 54
(4.0%) were negative. This difference just attains
statistical significance (p=0.05). Correspondingly,
one (0.7%) of 151 tests was negative in the six HI-
2 patients who developed the neuropathy compared
with 83 (4.8%) of 1715 tests in the 38 slow
inactivators in the HI-2 series who did not develop
this complication.  This difference is also statistically
significant (P=0.01). There was, therefore, evidence
in this study that the patients who developed
peripheral neuritis had taken their isoniazid tablets
more regularly than those who did not develop the
complication.
SEVERITY OF THE TUBERCULOSIS
Since peripheral neuritis may develop in patients
with tuberculosis in the absence of specific treatment
(Dixon, Roberts & Tyrrell, 1956), an analysis was
undertaken to see whether peripheral neuritis in this
study was associated with initially extensive
pulmonary disease. Of the 55 patients in the HI-1
and HI-2 series who had no cavitation or slight
cavitation six (11%) developed peripheral neuritis
compared with 13 (14%) of the 93 patients with
moderate or extensive cavitation.  The disease
involved one to three lung zones ion 58 patients and
of these seven (12%) developed the neuropathy
compared with 12 (13%) of 90 patients with four or
more zones involved. There was, therefore, hardly
any suggestion of an association of peripheral
neuritis with the initial extent of disease.
DISCUSSION
Isoniazid has been very widely used for the past
eight years in the treatment of pulmonary
tuberculosis. In low dosage, presumed side-effects
such as drowsiness, hyper-reflexia, tremors,
constipation, flushing and skin disorders are usually
mild and transient (Great Britain, Medical Research
Council,1952). With larger dosages the more serious
complication of peripheral neuritis is encountered.
Biehl & Nimitz (1954) reported a definite relation
TABLE 4
INCIDENCE OF PERIPHERAL NEURITIS RELATED TO THE PROPORTION OF NEGATIVE TEST
RESULTS ON URINE SPECIMENS COLLECTED AT ROUTINE VISITS TO THE CENTRE AMONG
THE PATIENTS CLASSIFIED AS SLOW INACTIVATORS OF ISONIAZID.
0 7 8 18 5
1-4 12 1 13 1
5 -9 6 2 2 0
10-14 2 0 0 0
15-19 0 0 2 0
20 or more 1 0 3 0
Total 28 11 38 6
patients
without peripheral
neuritis
Percentage of urine
tests with negative
results
         HI-1 HI-2
patients
with peripheral
neuritis
patients
without peripheral
neuritis
patients
with peripheral
neuritis
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between the dosage of isoniazid and the incidence
of peripheral neuritis, which rose from less than 10%
for a dosage of 6 mg/kg to 10 mg/kg body-weight
daily to 44% when the dosage was increased to 16
mg/kg to 24 mg/kg body-weight daily.
In the present study 19 cases of peripheral
neuritis with definite physical signs occurred in a
series of 148 tuberculous patients on a poor diet who
received isoniazid in a range of 7.8 mg/kg to 9.6
mg.kg body-weight daily, in higher one or two
doses. For the patients receiving two doses a day it
was 8%. However, the clinical response of the
tuberculosis to treatment was superior among the
former group of patients (Tuberculosis
Chemotherapy Centre, 1960 1 ). The difference in
the incidence of the peripheral neuritis between the
two dosage schedules does not attain statistical
significance and may therefore be a chance finding;
on the other hand it may be related to the higher
peak level of isoniazid in the serum which is
associated with the single dose (Gangadharam et al.,
to be published); there is no evidence that the patients
receiving one dose of isoniazid a day took their drug
more regularly than those on to doses a day
(Tuberculosis Chemotherapy Centre, 1960 1 ).  In
the United States Public Health Service (1954)
series, where a dosage of 10 mg/kg of the drug was
used, the occurrence of peripheral neuritis in a 12-
to 20-week
Period was 3.4%. In the series reported here, the
incidence in five months was 12% for patients
receiving the high dosage of isoniazid in one dose
daily and 3% for those receiving it in two doses
daily, the latter rate being similar to that observed
in the American series. We encountered only one
case of peripheral neuritis during a year of
chemotherapy among 190 patients on isoniazid 3.9
mg/kg to 5.5 mg/kg body-weight daily either alone
or in combination with PAS. Money (1959),
however, reported 16 cases (20%) of the neuropathy
among 84 malnourished patients in East Africa on
isoniazid 4 mg/kg to 6 mg/kg body-weight daily in
combination with PAS during a period of six to 12
months.
Not only was peripheral neuritis more frequent
in the patients receiving the isoniazid in one dose a
day but the onset was rather earlier than for those
on two doses a day; thus, nine out of 13 of the former
patients presented within the first six months
compared with two out of six of the latter. Biehl &
Nimitz (1954) reported that there was a tendency
for the neuritis to occur earlier with increasing
dosages of isoniazid. The United States Public
Health Service (1954) reported symptoms between
the 42nd and 95th day of treatment at a dosage of 10
mg/kg daily, with an average of 65 days, during on
observation period of 12 to 20 weeks. The symptoms
and signs of the peripheral neuritis in the present
series were mainly sensory in nature and  were
usually characterized by slow progression, in
keeping with the reports of Gammon, Burge & King
(1953) and Biehl & Nimitz (1954). Gammon, Burge
& King closely resembled arsenical neuropathy.
Only one patient in our series had evidence of a
mental disturbance, a complication reported by
several authors (Wiedorn & Ervin, 1954; Wood,
1955; Money, 1959).
There is evidence that isoniazid peripheral
neuritis is associated with a pyridoxine deficiency
state. Thus, pyridoxine has been used successfully
both in the prophylaxis (Biehl & Vilter, 1954;
Tchertkoff et al., 1956) and in the treatment of the
complication (Oestreicher, Dressler & Middlebrook,
1954; Tchert koff et al., 1956). Also, Biehl & Vilter
(1954) found an increase in the excretion of vitamin
B6 in the urine with isoniazid treatment and Vilter et
al. (1953) reported the occurrence of sensory neuritis
among patients treated with desoxypyridoxine, an
antagonist of pyridoxine. In eight of the cases
reported here the isoniazid was stopped and large
doses of pyridoxine were administered. All the
patients improved, but since the discontinuation of
isoniazid in itself results in improvement (Gammon,
Burge & King, 1953; Katz et al., 1954) it is not
possible to evaluate the part played by the pyridoxine
in the amelioration of the peripheral neuritis.
Wood (1955), Turner (personal communication,
1958) and Money (1959) have reported the efficacy
of vitamin B complex in the treatment of isoniazid
peripheral neuritis. Money (1959) treated 16 cases
with yeast tablets, while the isoniazid was continued.
Thirteen patients responded to this treatment and
the remaining three required parenteral vitamin B
complex. Turner (personal communication, 1958)
treated five cases who developed severe peripheral
neuritis, when receiving 1000 mg of isoniazid daily,
with a vitamin B complex preparation which did
not contain pyridoxine. Although the large dosage1
 See article on page 535 of this issue.
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of isoniazid was continued, the physical signs
disappeared with in a few weeks. In the present
series, seven cases of peripheral neuritis were treated
orally with a vitamin B complex preparation, four
of them continuing on the high dosage of isoniazid
and two on a reduced dosage, while the drug was
discontinued in the seventh case. All seven improved
even though the daily dosage of pyridoxine was only
6mg. There was therefore evidence that the vitamin
B complex used in this study exerted a beneficial
effect even when isoniazid  isoniazid was continued,
although the response in our patients was less
dramatic than that in Turner’s cases. It is difficult to
say which of the components of vitamin B complex
was responsible for the improvement of the neuritis.
In the preparation used, the pyridoxine content was
low. Other factors possibly responsible for the
improvement are thiamine and nicotinic acid. Lack
of thiamine is a well-known cause of peripheral
neuritis and it has been suggested that deficiency of
nicotinic acid may be responsible for the isoniazid
neuropathy (Jones & Jones, 1953).
It has been shown in this study that the mean
serum level of free isoniazid was higher in the
patients who developed peripheral neuritis than in
those who did not develop this complication on the
same high dosage of isoniazid and that the difference
between the incidence of peripheral neuritis in the
slow and in the rapid inactivators of isoniazid was
statistically significant. Our results therefore confirm
the findings of Biehl & Skavlem (1953) and are in
keeping with the urinary findings of Hughes et al.
(1954), who reported a higher incidence of
peripheral neuritis in those who inactivated isoniazid
(by acetylation) to a lesser degree. The dosage of
isoniazid is a factor of importance in the
development of peripheral neuritis, for only one case
was encountered among 190 patients on isoniazid
3.9 mg/kg to 5.5 mg/kg body-weight daily, either
alone or in combination with PAS, compared with
19 cases among 148 patients treated with isoniazid
7.8 mg/kg to 9.6 mg/kg body-weight daily.
However, within the higher dosage range, there was
no evidence that the patients who developed
peripheral neuritis had a higher mean daily dosage
than those who did not, the factor of importance
being the rate of isoniazid inactivation.
It may be conducted that since isoniazid given
in a dosage of 7.8 mg/kg to 9.6 mg/kg body-weight
daily produced a noteworthy incidence of peripheral
neuritis, especially when the drug was given in one
dose daily, dosage schedules of this order are
unsuitable for wide application in patients with a
poor diet (as in the community under study), unless
measures are taken to prevent the development of
the neuropathy. Although pyridoxine is effective in
the prophylaxis of this complication (Biehl & Vilter,
1954), its use is limited in under-developed countries
because of its high cost. In this study there was an
indication that the cheaper vitamin B complex may
have a beneficial effect on peripheral neuritis even
when patients continue to receive a high dosage of
isoniazid. The efficacy of vitamin B complex in the
prevention of the neuropathy is being investigated
and will be the subject of a further report.
SUMMARY
1. Twenty cases of peripheral neuritis due to
isoniazid were encountered in a chemotherapy study
in which 338 patients with previously untreated
pulmonary tuberculosis were allocated at random
to four treatment regimens for a year. These
regimens were:
Isoniazid in low dosage (3.9 mg/kg to 5.5 mg/kg
body weight daily) either
a) in combination with PAS, in two doses daily
         (PH regimen), or
b) alone, in two doses daily (H regimen).
Isoniazid in high dosage (7.8 mg/kg to 9.6 mg/kg
body-weight daily), given alone either
a) in one dose (HI-1 regimen), or
b) in two doses daily (HI-2 regimen).
2. One (1%) case of peripheral neuritis occurred
among the 96 PH patients, none among the 94 H
patients, 13 (18%) among the 74 HI-1 patients and
six (8%) among the 74 HI-2 patients.
3. The time of onest of symptoms of peripheral
neuritis ranged from the second month to the tenth
month of treatment, and was earlier in the HI-1
patients than in the HI-2 patients.
4. The symptoms and signs were mainly sensory in
nature (with loss of reflexes) and there was slow
progression. Five patients also developed muscular
weakness. One case (HI-1) with peripheral neuritis
also exhibited signs of mental disturbance.
5.  Nine cases were treated with pyriodoxine; in eight
of them the isoniazid was discontinued. Gradual
improvement was noted.
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6. Seven cases were treated with vitamin B complex,
six continuing on isoniazid, the dosage being
lowered in two. All seven cases improved.
7. Three cases with very mild peripheral neuritis
improved spontaneously without any specific
treatment and without discontinuing the isoniazid.
8. The only patient who developed peripheral
neuritis in the PH series improved with
discontinuation of the chemotherapy and treatment
with vitamin B Complex.
On sait que la névrite péripherique peut etre une
complication due traitement de la tuberculose par
1’sioniazide (INH). Elle est rare si le médicament est
administré à petities doses. Mais récemment des cas
proportion nellement nombreux sont survenus en
Afrique orientale, parmi des tuberculeux souffrant de
malnutrition, soumis à une cure d’INH d’une annee et
recevant des doses relativement faibles de ce
medicament (4-6 mg /kg de poids corporel).
Cette étude est consacrée à 1’examen de 20 cas de
névrite périphérique observés à Madras, Inde, parmi
338 malades souffrant de malnutrition, an cours d’une
cure d’INH, comportant pour les uns 3, 9-5, 5 mg/kg
et pour les autres des doses plus fortes, de 7, 8-9, 6 mg
/ kg.  19 cas sur ces 20 se produisirent dans le groupe
recevant la dose la plus élevée. On trouva chez eux un
9. Serum isoniazid assays were performed in 143 of
the 148 patients allocated to the HI-1, and HI-2,
regimens. Considering both series together, the 19
patients with peripheral neuritis had a higher mean
serum level of isoniazid when compared with that
of the 124 patients who did not develop this
complication. The difference between the incidence
of peripheral neuritis in the slow and in the rapid
inactivators of isoniazid attained statistical
significance.
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RESUME
taux sanguin d’INH libre superieur à celui des sujets
ne présentant pas de complication. La névrite est
apparue du 2e au 10e mois de traitement. Les
symptômes étaient essentiellement sensoriels, avec
perte des réflexes, et progression lente. Cinq malades
présenterent de la faiblesse musculaire, et un des
troubles mentaux. Les cas les plus béninis guerirent
spontanément, sans meme que l’on interrrompe le
traitement. La pyridoxine ou le complexe vitaminique
B furent efficaces dans les autres cas. Les auteurs
estiment qu’une posologies quotidienne de 7, 8-9, 6
mg/kg est excessive pour la therapie de masse, chez
des populations mal nourries, à moins que l’on ne
previenne les complications par l’administration due
complexe vitaminique B, moins couteux que la
pyridoxine.
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